US5036056A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for treating damaged corneal, uterine, or cartilage tissue
Assignee: Individual
•
Filing: 1990-03-27
•
Granted: 1991-07-30
•
Expires: 2010-03-27
Abstract
Abstract Methods for treating damaged corneal, uterine or cartilage tissue comprising applying a therapeutically effective amount of a composition comprising: (a) a sterile extracellular connective tissue matrix composition comprising collagens, proteoglycans, glycosaminoglycans and glycoproteins wherein said collagens, said proteoglycans, said glycosamino glycans, and said glycoproteins have each been extracted from an extracellular connective tissue matrix and are in their native structural form and (b) a pharmaceutically acceptable carrier.
Inventors
- 👤 Martin Kludas
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 03:51
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K35/00; A61K35/12; A61K35/44; A61K35/48; A61K35/50; A61K38/00; A61K38/16; A61K38/17; A61K38/39; C; C07; C07K; C07K14/00; C07K14/435; C07K14/78
Claims Analysis
Total Claims: 34
Claim 1
Independent Claim
67 words
A method of treating a damaged cornea comprising applying to said cornea a therapeutically effective amount of a composition comprising: (a) a sterile extracellular connective tissue matrix composition comprising collagens, proteoglycans, glycosaminoglycans and glycoproteins, wherein said collagens, said proteoglycans, said glycosaminoglycans, and said glycoproteins have each been extracted from an extracellular connective tissue matrix and are in their native structural form, and (b) a pharmaceutically acceptable carrier.
Claim 2
Independent Claim
67 words
A method of treating a damaged cornea comprising applying to said cornea a therapeutically effective amount of a composition comprising: (a) a sterile extracellular connective tissue matrix composition comprising collagens, proteoglycans, glycosaminoglycans and glycoproteins, wherein said collagens, said proteoglycans, said glycosaminoglycans, and said glycoproteins have each been extracted from an extracellular connective tissue matrix and are in their native structural form, and (b) a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
20 words
The method of claim 1 wherein the sterile extracellular connective tissue matrix composition and pharmaceutically acceptable carrier is applied topically.
Claim 4
Dependent Claim
18 words
The method of claim 1 wherein the sterile extracellular connective tissue matrix composition is derived from a mammal.
Claim 5
Dependent Claim
28 words
The method of claim 1 wherein the sterile extracellular connective tissue matrix composition is derived from an animal selected from the group consisting of bovine, ovine and porcine.
Claim 6
Dependent Claim
33 words
The method of claim 3 wherein the sterile extracellular connective tissue matrix composition is derived from the tissue selected from the group consisting of placenta tissue, fetal membranes, blood vessels and umbilical cords.
Claim 7
Dependent Claim
18 words
The method of claim 1 wherein the collagens comprise collagen types I, III, IV, V, VI and VII.
Claim 8
Dependent Claim
14 words
The method of claim 6 wherein the proteoglycans and glycosaminoglycans are solubilized and intact.
Claim 9
Dependent Claim
21 words
The method of claim 1 wherein the sterile extracellular connective tissue matrix composition comprises at least about 0.1% of said mixture.
Claim 10
Dependent Claim
25 words
The method of claim 1 wherein the sterile extracellular connective tissue matrix composition is applied at least about once a day to said damaged cornea.
Claim 11
Dependent Claim
46 words
The method of claim 1 wherein said composition comprising said sterile extracellular connective tissue matrix composition and said pharmaceutically acceptable carrier is applied to the cornea over a period of time sufficient to reduce the time required to complete the healing process of the damaged cornea.
Claim 12
Independent Claim
69 words
A method of treating damaged cartilage tissue comprising applying to said damaged cartilage tissue a therapeutically effective amount of a composition comprising: (a) a sterile extracellular connective tissue matrix composition comprising collagens, proteoglycans, glycosaminoglycans and glycoproteins, wherein said collagens, said proteoglycans, said glycosaminoglycans, and said glycoproteins have each been extracted from an extracellular connective tissue matrix and are in their native structural form, and (b) a pharmaceutically acceptable carrier.
Claim 13
Independent Claim
69 words
A method of treating damaged cartilage tissue comprising applying to said damaged cartilage tissue a therapeutically effective amount of a composition comprising: (a) a sterile extracellular connective tissue matrix composition comprising collagens, proteoglycans, glycosaminoglycans and glycoproteins, wherein said collagens, said proteoglycans, said glycosaminoglycans, and said glycoproteins have each been extracted from an extracellular connective tissue matrix and are in their native structural form, and (b) a pharmaceutically acceptable carrier.
Claim 14
Dependent Claim
15 words
The method of claim 11 wherein the damage to the cartilage is caused by arthritis.
Claim 15
Dependent Claim
17 words
The method of claim 11 wherein the composition is provided to the damaged cartilage by intraarticular injection.
Claim 16
Dependent Claim
18 words
The method of claim 11 wherein the sterile extracellular connective tissue matrix composition is derived from a mammal.
Claim 17
Dependent Claim
28 words
The method of claim 11 wherein the sterile extracellular connective tissue matrix composition is derived from an animal selected from the group consisting of bovine, ovine and porcine.
Claim 18
Dependent Claim
33 words
The method of claim 14 wherein the sterile extracellular connective tissue matrix composition is derived from the tissue selected from the group consisting of placenta tissue, fetal membranes, blood vessels and umbilical cords.
Claim 19
Dependent Claim
18 words
The method of claim 39 wherein the collagens comprise collagen types I, III, IV, V, VI and VII.
Claim 20
Dependent Claim
14 words
The method of claim 39 wherein the proteoglycans and glycosaminoglycans are solubilized and intact.
Claim 21
Dependent Claim
21 words
The method of claim 11 wherein the sterile extracellular connective tissue matrix composition comprises at least about 0.1% of said mixture.
Claim 22
Dependent Claim
25 words
The method of claim 11 wherein the sterile extracellular connective tissue matrix composition is provided at least about once a day to said damaged cartilage.
Claim 23
Dependent Claim
46 words
The method of claim 11 wherein said composition comprising said sterile extracellular connective tissue matrix composition and said pharmaceutically acceptable carrier is provided to the cartilage over a period of time sufficient to reduce the time required to complete the healing process of the damaged cartilage.
Claim 24
Independent Claim
69 words
A method for treating damaged uterine tissue comprising applying to said damaged uterine tissue a therapeutically effective amount of a composition comprising: (a) a sterile extracellular connective tissue matrix composition comprising collagens, proteoglycans, glycosaminoglycans and glycoproteins, wherein said collagens, said proteoglycans, said glycosaminoglycans, and said glycoproteins have each been extracted from an extracellular connective tissue matrix and are in their native structural form, and (b) a pharmaceutically acceptable carrier.
Claim 25
Independent Claim
69 words
A method for treating damaged uterine tissue comprising applying to said damaged uterine tissue a therapeutically effective amount of a composition comprising: (a) a sterile extracellular connective tissue matrix composition comprising collagens, proteoglycans, glycosaminoglycans and glycoproteins, wherein said collagens, said proteoglycans, said glycosaminoglycans, and said glycoproteins have each been extracted from an extracellular connective tissue matrix and are in their native structural form, and (b) a pharmaceutically acceptable carrier.
Claim 26
Dependent Claim
20 words
The method of claim 22 wherein the sterile extracellular connective tissue matrix composition and pharmaceutically acceptable carrier is applied topically.
Claim 27
Dependent Claim
18 words
The method of claim 22 wherein the sterile extracellular connective tissue matrix composition is derived from a mammal.
Claim 28
Dependent Claim
28 words
The method of claim 22 wherein the sterile extracellular connective tissue matrix composition is derived from an animal selected from the group consisting of bovine, ovine and porcine.
Claim 29
Dependent Claim
33 words
The method of claim 24 wherein the sterile extracellular connective tissue matrix composition is derived from the tissue selected from the group consisting of placenta tissue, fetal membranes, blood vessels and umbilical cords.
Claim 30
Dependent Claim
18 words
The method of claim 22 wherein the collagens comprise collagen types I, III, IV, V, VI and VII.
Claim 31
Dependent Claim
14 words
The method of claim 22 wherein the proteoglycans and glycosaminoglycans are solubilized and intact.
Claim 32
Dependent Claim
21 words
The method of claim 22 wherein the sterile extracellular connective tissue matrix composition comprises at least about 0.1% of said mixture.
Claim 33
Dependent Claim
25 words
The method of claim 22 wherein the sterile extracellular connective tissue matrix composition is applied at least about once a day to said damaged uterus.
Claim 34
Dependent Claim
48 words
The method of claim 22 wherein said composition comprising said sterile extracellular connective tissue matrix composition and said pharmaceutically acceptable carrier is applied to the uterine tissue over a period of time sufficient to reduce the time required to complete the healing process of the damaged uterine tissue.
References Cited (Backward Citations)
US3887703A
Cited
US3839590A
Cited
GB1386864A
Cited
US3991184A
Cited
US4108849A
Cited
FR2299019A1
Cited
US4488911A
Cited
US4042457A
Cited
USRE30239E
Cited
US4296099A
Cited
US4327078A
Cited
US4228153A
Cited
FR2487197A2
Cited
US4389487A
Cited
US4642292A
Cited
US4464362A
Cited
US4420339A
Cited
US4511653A
Cited
US4451397A
Cited
EP0128706A2
Cited
US4448718A
Cited
EP0154447A2
Cited
US4696813A
Cited
US4664110A
Cited
FR2591107A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-07-29 | 1995-01-28 | 1995-07-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-07-29 | 1999-01-28 | 1999-07-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-07-29 | 2003-01-28 | 2003-07-30 | $7700.00 | Window Closed / Lapsed |